Pediatric obesity: an inflammatory condition?

Jennifer Sacheck1

  • 1John Hancock Center for Physical Activity and Nutrition, Friedman School of Nutrition Science and Policy at Tufts University, Boston, Massachusetts 02111, USA. jennifer.sacheck@tufts.edu

Insights

Childhood obesity is rising, increasing metabolic risks like inflammation in youth. Diet and exercise may help, but more research and better biomarkers are needed to track these changes.

Area of Science:

  • Pediatric Endocrinology
  • Nutritional Science
  • Inflammation Research

Background:

  • Childhood obesity rates are increasing globally.
  • This rise is linked to metabolic risk factors, including dyslipidemia and inflammation.
  • These factors contribute to chronic diseases like type 2 diabetes and cardiovascular disease.

Purpose of the Study:

  • To review the impact of diet and exercise on inflammation in children.
  • To highlight the need for prospective studies in this area.
  • To discuss the limitations of current inflammation biomarkers in youth.

Main Methods:

  • Literature review of recent research on childhood obesity, inflammation, diet, and exercise.
  • Analysis of current biomarkers for inflammation and metabolic risk in pediatric populations.
  • Discussion of potential novel biomarkers.

Main Results:

  • Elevated triglycerides and low high-density lipoprotein are common metabolic risks.
  • Inflammatory biomarkers like C-reactive protein and interleukin-6 are increased in obese children.
  • Dietary antioxidants, omega-3 fatty acids, physical activity, and fitness may independently reduce inflammation.

Conclusions:

  • Diet and exercise interventions show promise in modifying inflammation associated with childhood obesity.
  • Prospective research is crucial to confirm these effects.
  • Novel biomarkers are needed to accurately detect subtle inflammatory changes in at-risk youth.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...